key: cord-0940912-hkm9agqg
authors: Thorlund, Kristian; Dron, Louis; Park, Jay; Hsu, Grace; Forrest, Jamie I; Mills, Edward J
title: A real-time dashboard of clinical trials for COVID-19
date: 2020-04-24
journal: Lancet Digit Health
DOI: 10.1016/s2589-7500(20)30086-8
sha: e86d013d304371081133d6b67b4884019d6d0c12
doc_id: 940912
cord_uid: hkm9agqg

nan

In response to the global coronavirus disease 2019 (COVID-19) emergency, clinical trial research assessing the efficacy and safety of clinical candidate interventions to treat COVID-19 are emerging at an unprecedented rate. As of April 21, 2020, well over 500 clinical trials have been registered at the various international and national clinical trial registry sites. Findings from randomised clinical trials that have been published as of April 21, 2020, have investigated the efficacy of lopinavir-ritonavir compared with standard of care, 1 hydroxychloroquine compared with best supportive care, 2 favipiravir compared with arbidol, 3 and lopinavir-ritonavir compared with arbidol. 4 Other non-randomised trials have investigated hydroxychloroquine versus hydroxychloroquine combined with azithromycin. 5 Over 300 trials are enrolling participants and cover further investigations of the above drugs and promising therapies such as remdesivir, IL-6 inhibitors (tocilizumab and sarilumab), convalescent plasma therapy, stem-cell transfusion, vaccine candidates, several other well known direct acting antiv irals, and traditional Chinese medicines. Most of these trials will offer comparative efficacy data versus standard of care according to local COVID-19 treatment guidelines, but a handful of randomised controlled trials will also provide headto-head evidence between high profile interventions. The figure shows the network of completed, ongoing, and planned COVID-19 interventional clinical trials of these interventions or intervention groups that are being explored in at least two trials.

Given methods provide estimates of the likelihood of importance of a study being included in our database, such that the study can then be reviewed manually for inclusion. Use of AI-based methods saves 50-80% of the time required to manually review all entries without loss of accuracy. Finally, we will use content aggregator services, such as LitCovid, to ensure our data acquisition strategy is complete. With this three-step process, the probability of missing important publications is greatly diminished and so the resulting data are representative of global COVID-19 research efforts. Trials for COVID-19 are then mapped according to geographical, trial, patient, and intervention characteristics, when these data are available. These data are stored securely in a backend database and outputs are visualised on a frontend feature.

A pilot study of hydroxychloroquine in treatment of patients with common coronavirus disease-19 (COVID-19)

Favipiravir versus arbidol for COVID-19: a randomized clinical trial

In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus

Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial